The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback